Rationale: Patients with atopic dermatitis undergoing penetrating keratoplasty (PKP) face a high risk of postoperative complications. Endothelial keratoplasty may be a safer alternative for such patients, including those with abnormal anterior chamber anatomy.
Patient Concerns: 3 male patients, aged 33 to 44, presented with blurred vision at Keio University Hospital.
Diagnosis: Bullous keratopathy was diagnosed through slit-lamp examination and specular microscopy. Two patients had well-controlled systemic atopic dermatitis, while 1 had blepharitis associated with atopic dermatitis. Two patients had peripheral anterior synechia, and 2 had undergone glaucoma surgery before keratoplasty.
Interventions: Non-Descemet stripping endothelial keratoplasty (nDSAEK) was performed by a single surgeon.
Outcomes: The best-corrected visual acuity ranged from 0.7 to 1.5 logMAR before surgery and from 0.2 to 2.3 logMAR after surgery. One year post-surgery, the graft remained clear in 2 cases; however, in the case of repeated glaucoma surgeries after nDSAEK, the graft became edematous. Corneal endothelial cell density was 1586 and 1988 cells/mm² in 2 cases and undetectable in the failed case. The follow-up period ranged from 2.5 to 9 years.
Lessons: Despite the presence of peripheral anterior synechia or prior glaucoma surgery, some patients experienced a favorable long-term postoperative course following nDSAEK. This procedure may offer a safer alternative for treating patients with atopic dermatitis who have ocular complications that present a high risk for PKP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441933 | PMC |
http://dx.doi.org/10.1097/MD.0000000000039767 | DOI Listing |
Phytother Res
January 2025
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
Atopic dermatitis (AD) is a common inflammatory dermatitis of the skin and poses therapeutic challenges due to the adverse reactions and high costs associated with available treatments. In Eastern Asian countries, a plethora of herbal remedies is extensively employed for the alleviation of AD. Many of these botanicals are renowned for their formidable anti-inflammatory properties, contributing to AD management.
View Article and Find Full Text PDFJ Med Biogr
January 2025
Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Eugène Hertoghe (1860-1928), a Belgian internist and former vice-president of the Royal Academy of Medicine of Belgium, made significant contributions to the understanding and treatment of chronic hypothyroidism. He provided a detailed clinical description of the condition, emphasizing its multisystemic manifestations and hereditary aspects. Hertoghe also documented the therapeutic use of thyroid extract, reporting its effectiveness in alleviating symptoms of hypothyroidism.
View Article and Find Full Text PDFThe stress-induced keratin intermediate filament gene/protein (K16) is spatially restricted to the suprabasal compartment of the epidermis and extensively used as a biomarker for psoriasis, hidradenitis suppurativa, atopic dermatitis and other inflammatory disorders. However, its role in these conditions remains poorly defined. Here we show that K16 negatively regulates type-I interferon (IFN) signaling and innate immune responses.
View Article and Find Full Text PDFClin Exp Allergy
January 2025
National Clinical Research Center for Child Health and Disorders, Department of Dermatology, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
J Dermatolog Treat
December 2025
Sanofi-Evidence Generation and Dissemination Manager Greater Gulf, UAE.
Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.
Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!